Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease

Don Monath Sanjaya Kuruppu, Niwanthi Wickramasekara Rajapakse, Alexander Ian Smith

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Endothelin is one of the most potent peptide vasoconstrictors thus far characterised. It is produced by the cleavage of its precursor big endothelin-1 by endothelin-converting enzyme-1 (ECE-1). The endothelin system which includes endothelin-1 (ET-1), ET receptors and ECE-1 is well characterised in the kidney and is known to play a key role in the pathogenesis of end-stage renal disease (ESRD). Therefore, inhibition of ECE-1 and antagonism of ET receptors represent potential therapeutic approaches for the treatment of ESRD. Here, we review the current literature on the localisation of ECE-1 in the normal kidney and how ECE-1 expression is altered in pathological conditions leading to ESRD. We also discuss the roles of neutral endopeptidase (NEP) and chymase in mediating the production of ET-1 in the kidney in ESRD. As such, we also discuss that complete inhibition of ET-1 production in the kidney requires the inhibition of ECE-1, NEP and chymase.
Original languageEnglish
Pages (from-to)929 - 934
Number of pages6
JournalPflugers Archiv-European Journal of Physiology
Volume465
Issue number7
DOIs
Publication statusPublished - 2013

Cite this

@article{48fd88227ca3411d936c90c32d318360,
title = "Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease",
abstract = "Endothelin is one of the most potent peptide vasoconstrictors thus far characterised. It is produced by the cleavage of its precursor big endothelin-1 by endothelin-converting enzyme-1 (ECE-1). The endothelin system which includes endothelin-1 (ET-1), ET receptors and ECE-1 is well characterised in the kidney and is known to play a key role in the pathogenesis of end-stage renal disease (ESRD). Therefore, inhibition of ECE-1 and antagonism of ET receptors represent potential therapeutic approaches for the treatment of ESRD. Here, we review the current literature on the localisation of ECE-1 in the normal kidney and how ECE-1 expression is altered in pathological conditions leading to ESRD. We also discuss the roles of neutral endopeptidase (NEP) and chymase in mediating the production of ET-1 in the kidney in ESRD. As such, we also discuss that complete inhibition of ET-1 production in the kidney requires the inhibition of ECE-1, NEP and chymase.",
author = "Kuruppu, {Don Monath Sanjaya} and Rajapakse, {Niwanthi Wickramasekara} and Smith, {Alexander Ian}",
year = "2013",
doi = "10.1007/s00424-013-1216-1",
language = "English",
volume = "465",
pages = "929 -- 934",
journal = "Pflugers Archiv-European Journal of Physiology",
issn = "0031-6768",
publisher = "Springer-Verlag London Ltd.",
number = "7",

}

Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease. / Kuruppu, Don Monath Sanjaya; Rajapakse, Niwanthi Wickramasekara; Smith, Alexander Ian.

In: Pflugers Archiv-European Journal of Physiology, Vol. 465, No. 7, 2013, p. 929 - 934.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease

AU - Kuruppu, Don Monath Sanjaya

AU - Rajapakse, Niwanthi Wickramasekara

AU - Smith, Alexander Ian

PY - 2013

Y1 - 2013

N2 - Endothelin is one of the most potent peptide vasoconstrictors thus far characterised. It is produced by the cleavage of its precursor big endothelin-1 by endothelin-converting enzyme-1 (ECE-1). The endothelin system which includes endothelin-1 (ET-1), ET receptors and ECE-1 is well characterised in the kidney and is known to play a key role in the pathogenesis of end-stage renal disease (ESRD). Therefore, inhibition of ECE-1 and antagonism of ET receptors represent potential therapeutic approaches for the treatment of ESRD. Here, we review the current literature on the localisation of ECE-1 in the normal kidney and how ECE-1 expression is altered in pathological conditions leading to ESRD. We also discuss the roles of neutral endopeptidase (NEP) and chymase in mediating the production of ET-1 in the kidney in ESRD. As such, we also discuss that complete inhibition of ET-1 production in the kidney requires the inhibition of ECE-1, NEP and chymase.

AB - Endothelin is one of the most potent peptide vasoconstrictors thus far characterised. It is produced by the cleavage of its precursor big endothelin-1 by endothelin-converting enzyme-1 (ECE-1). The endothelin system which includes endothelin-1 (ET-1), ET receptors and ECE-1 is well characterised in the kidney and is known to play a key role in the pathogenesis of end-stage renal disease (ESRD). Therefore, inhibition of ECE-1 and antagonism of ET receptors represent potential therapeutic approaches for the treatment of ESRD. Here, we review the current literature on the localisation of ECE-1 in the normal kidney and how ECE-1 expression is altered in pathological conditions leading to ESRD. We also discuss the roles of neutral endopeptidase (NEP) and chymase in mediating the production of ET-1 in the kidney in ESRD. As such, we also discuss that complete inhibition of ET-1 production in the kidney requires the inhibition of ECE-1, NEP and chymase.

UR - http://goo.gl/WMYw7V

U2 - 10.1007/s00424-013-1216-1

DO - 10.1007/s00424-013-1216-1

M3 - Article

VL - 465

SP - 929

EP - 934

JO - Pflugers Archiv-European Journal of Physiology

JF - Pflugers Archiv-European Journal of Physiology

SN - 0031-6768

IS - 7

ER -